Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neurofibromatosis 2

• Doxycycline in Cutaneous Schwannoma (NF2)
• Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
• Study of Aspirin in Patients With Vestibular Schwannoma
• Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
• Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
• Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
• Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
• Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
• Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
• Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
• Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
• PTC299 for Treatment of Neurofibromatosis Type 2
• Concentration and Activity of Lapatinib in Vestibular Schwannomas